Insider Trading Activity Biogen (NASDAQ:BIIB) – Director Bought 48,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Biogen (NASDAQ:BIIB)

Alexander J Denner , Director of Biogen (NASDAQ:BIIB) reportedly Bought 48,000 shares of the company’s stock at an average price of 269.91 for a total transaction amount of $12,955,680.00 SEC Form

Insider Trading History For Biogen (NASDAQ:BIIB)

  • On 12/27/2012 Alexander J Denner, Director, sold 7,980 with an average share price of $148.62 per share and the total transaction amounting to $1,185,987.60.
  • On 5/28/2013 Robert W Pangia, Director, sold 5,900 with an average share price of $237.23 per share and the total transaction amounting to $1,399,657.00.
  • On 6/3/2013 Stephen A Sherwin, Director, sold 12,825 with an average share price of $233.26 per share and the total transaction amounting to $2,991,559.50.
  • On 6/3/2013 George A Scangos, CEO, sold 1,598 with an average share price of $234.16 per share and the total transaction amounting to $374,187.68.
  • On 6/10/2013 Lynn Schenk, Director, sold 2,000 with an average share price of $225.82 per share and the total transaction amounting to $451,640.00.
  • On 6/11/2013 Brian S Posner, Director, sold 2,020 with an average share price of $219.62 per share and the total transaction amounting to $443,632.40.
  • On 6/14/2013 Alexander J Denner, Director, sold 2,900 with an average share price of $212.00 per share and the total transaction amounting to $614,800.00.

    • Analyst Ratings History For Biogen (NASDAQ:BIIB)

    • On 6/8/2016 Wells Fargo Reiterated Rating Buy
    • On 8/2/2016 Standpoint Research Downgraded rating Buy to Hold
    • On 3/1/2017 Instinet Initiated Coverage of rating Buy to Buy with a price target of $223.03 to $345.00
    • On 9/21/2017 Raymond James Downgraded rating Strong-Buy to Market Perform with a price target of $244.28 to $319.00
    • On 10/18/2017 Bank of America Boost Price Target of rating Buy with a price target of $358.00 to $365.00
    • On 12/30/2017 Nomura Boost Price Target of rating Buy with a price target of $355.00 to $420.00
    • On 1/26/2018 HC Wainwright Reiterated Rating Buy to Buy with a price target of $340.00 to $363.00

    Recent Trading Activity for Biogen (NASDAQ:BIIB)
    Shares of Biogen closed the previous trading session at 276.44 up +2.58 0.94% with 274.3110046386719 shares trading hands.